	UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549

	SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

Martek Biosciences Corporation

(Name of Issuer)

Common Stock, $0.10 par value

(Title of Class of Securities)

572901106

(CUSIP Number)

Hugh C. Welsh

President and General Counsel

DSM North America

45 Waterview Boulevard

Parsippany, NJ 07054

(973) 257-8300

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

Copies to:

William A. Groll

David Leinwand

Cleary Gottlieb Steen & Hamilton LLP

One Liberty Plaza

New York, New York 10006

(212) 225-2000

February 25, 2011

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 572901106						13D

	1	Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (Entities Only) Koninklijke DSM N.V.

	2	Check the Appropriate Box if a Member of a Group
		(a)			o
		(b)			x

	3	SEC Use Only

	4	Source of Funds WC, PF

	5	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o

	6	Citizenship or Place of Organization The Netherlands

Number of Shares Beneficially Owned by Each Reporting Person With			7	Sole Voting Power (See Item 5)

			8	Shared Voting Power 0

			9	Sole Dispositive Power (See Item 5)

			10	Shared Dispositive Power 0

	11	Aggregate Amount Beneficially Owned by Each Reporting Person (See Item 5)

	12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares o

	13	Percent of Class Represented by Amount in Row (11) 100% (See Item 5)

	14	Type of Reporting Person CO

This Amendment No. 1 to Schedule 13D (this “Amendment”) relates to the common stock, par value $0.10 per share (the “Shares”), of Martek Biosciences Corporation, a Delaware corporation (“Martek”). The principal executive offices of Martek are located at 6480 Dobbin Road, Columbia, Maryland 21045. This Amendment is being filed by Koninklijke DSM N.V. (“DSM”) to amend its disclosure under Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which, in accordance with Instruction H of the General Instructions to Schedule TO, constituted part of the Schedule TO initially filed by DSM on January 13, 2011, as amended, including by Amendment No. 7 thereto (the final amendment) filed on February 25, 2011 (the “Schedule TO”).

Item 4. Purpose of Transaction

Pursuant to an Agreement and Plan of Merger, dated as of December 20, 2010, by and among DSM, Greenback Acquisition Corporation, a Delaware corporation (“Greenback”) and Martek (the “Merger Agreement”), on January 13, 2011, DSM and Greenback commenced a tender offer (the “Offer”) for all of the outstanding Shares and filed the Schedule TO with the Securities and Exchange Commission (the “SEC”). On February 25, 2011, following completion of the Offer, DSM exercised the top-up option that was granted to it pursuant to the Merger Agreement and purchased additional Shares directly from Martek. Shortly thereafter, Greenback was merged with and into Martek and Martek, as the surviving corporation (the “Surviving Corporation”), became an indirect wholly owned subsidiary of DSM (the “Merger”). At the effective time of the Merger (the “Effective Time”), each outstanding Share (other than Shares held in the treasury of Martek or owned by DSM or any subsidiary of DSM or Martek or held by stockholders who properly demand and perfect appraisal rights under the Delaware General Corporation Law (“DGCL”)) was canceled and converted into the right to receive an amount in cash, without interest and subject to applicable withholding taxes, equal to $31.50.

In accordance with the terms of the Merger Agreement, upon the completion of the Merger, the directors of Greenback immediately prior to the Effective Time became the directors of the Surviving Corporation. The Shares are no longer listed for trading on the NASDAQ Global Select Market, and DSM intends to cause the Surviving Corporation to effect the termination of registration of the Shares with the SEC in accordance with the applicable requirements of the federal securities laws.

Item 5. Interest in Securities of the Issuer

(a) - (b) As a result of the Merger, DSM beneficially owns 100% of the issued and outstanding shares of the Surviving Corporation.

Item 7. Material to be Filed as Exhibits

Exhibit 1 Press Release issued by DSM on February 28, 2011

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 28, 2011

KONINKLIJKE DSM N.V.


By:	/s/ Hugh C. Welsh
	Name:	Hugh C. Welsh
	Title:	President and General Counsel, DSM North America

EXHIBIT INDEX

Exhibit 1

Press Release issued by DSM on February 28, 2011

MARTEK BIOSCIENCES CORP SC 13D/A